Arthneeti
All Q2 FY26 results →
SA

Solara Active

Q2 FY26Pharmaceuticals & Biotechnology

Solara Active Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹629
Market cap₹2.9K Cr
P/E690.5
Updated26 Aug 2026
Read4 min read

The short version

The company aims for at least 3-4 quarters of growth to demonstrate a strong turnaround. Solara aims for sustainable, scalable, and profitable growth moving forward, focusing on 3-4 quarters of consistent growth to demonstrate a turnaround.

From Solara Active's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • The company aims for at least 3-4 quarters of growth to demonstrate a strong turnaround.
  • They have an outlook of approximately 10% sales/revenue growth.
  • Growth will come from expanding into new markets beyond the US, Europe, and Japan, including Latin America, South Korea, and the Middle East.
  • Current facility capacity utilization is about 70%, with capacity available to serve new customers.
  • Incremental sales will be focused on higher-margin and value-added product lines such as ibuprofen derivatives.
  • The R&D pipeline is being developed, but new product approvals and launches are expected over a 2-3 year time horizon.

2 more points from Solara Active's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Solara Active said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is not planning any big capital investments currently due to liquidity constraints.
  • Capex is focused on small, bite-sized investments primarily aimed at debottlenecking existing capacity.
  • Ongoing capex projects are designed to be executed on time to increase capacity and support future growth.
  • No specific capex figures for upcoming periods were provided; investment plans will depend on how existing projects progress.

2 more points from Solara Active's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Solara Active said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Solara Active Pharma Sciences has experienced some short-term disruptions impacting production (Page 12).
  • Despite a 4-week operational shutdown, management indicated the lost sales orders have not been lost permanently and will be fulfilled in the next two quarters or by Q4 if delayed (Page 12).
  • The company expects to service deferred revenue/orders by utilizing available capacity in coming quarters, aiming to catch up on production backlog (Page 12).
  • Facility utilization stands around 70%, with available capacity to cater to new and existing markets (Page 13).

2 more points from Solara Active's call on order book

Pro opens every point from 15K+ earnings calls

Solara Active — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Solara Active and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Solara Active Q2 FY26 results?

The company aims for at least 3-4 quarters of growth to demonstrate a strong turnaround. Solara aims for sustainable, scalable, and profitable growth moving forward, focusing on 3-4 quarters of consistent growth to demonstrate a turnaround.

What is Solara Active share price analysis?

Solara Active currently shows a neutral. The stock trades at a P/E of 690.5 with a market cap of ₹2,948 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active planning capital expenditure?

The company is not planning any big capital investments currently due to liquidity constraints.

Keep Solara Active on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.